Holen Sie sich die Stockscreener-App
0.3061
9.94%
-0.0338
Handel nachbörslich:
.32
0.0139
+4.54%
Schlusskurs vom Vortag:
$0.3399
Offen:
$0.32
24-Stunden-Volumen:
2.53M
Relative Volume:
0.47
Marktkapitalisierung:
$39.00M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-0.2041
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
-17.76%
1M Leistung:
-36.23%
6M Leistung:
-84.85%
1J Leistung:
-93.12%
1-Tages-Spanne:
$0.3061
$0.3324
1-Wochen-Bereich:
$0.3061
$0.42
52-Wochen-Spanne:
$0.3061
$4.64
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.3061 | 39.00M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | William Blair | Outperform |
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
When Would Be The Best Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - stocksregister.com
Mersana Therapeutics Announces Upcoming Oral Presentation - GlobeNewswire
FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 - Stock Titan
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
MRSN stock plunges to 52-week low of $0.37 amid market challenges - Investing.com India
MRSN stock plunges to 52-week low of $0.37 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st
MRSN stock touches 52-week low at $0.43 amid sharp decline - Investing.com India
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MRSN stock plunges to 52-week low of $0.45 amid market challenges - Investing.com Australia
Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights By Investing.com - Investing.com Canada
MRSN stock plunges to 52-week low of $0.45 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush - MarketBeat
Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Simply Wall St
Mersana Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Brokers Issue Forecasts for MRSN Q1 Earnings - Defense World
Q1 EPS Estimate for Mersana Therapeutics Reduced by Analyst - Defense World
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Yahoo Finance
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript - Insider Monkey
Mersana Therapeutics (NASDAQ:MRSN) Receives “Outperform” Rating from Wedbush - Defense World
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges - TipRanks
Mersana Therapeutics Reports Progress and Financial Results - TipRanks
Mersana Therapeutics’ Earnings Call Highlights Clinical Progress and Financial Gains - TipRanks
Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast By Investing.com - Investing.com Canada
Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast - Investing.com India
Mersana Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mersana Therapeutics reports Q4 EPS (11c), consensus (17c) - TipRanks
Mersana Therapeutics, Inc. SEC 10-K Report - TradingView
Mersana Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Mersana Therapeutics Announces Positive Phase 1 Clinical Data - TipRanks
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Mersana's ADC Pipeline Advances: FDA Fast Track Designation as Q4 Losses Narrow - StockTitan
What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings - GuruFocus.com
MRSN stock touches 52-week low at $0.49 amid sharp annual decline - Investing.com Australia
William Blair starts Mersana stock with Outperform rating - MSN
Mersana Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
Mersana Therapeutics faces Nasdaq delisting over share price - Investing.com
MRSN stock touches 52-week low at $0.49 amid sharp annual decline By Investing.com - Investing.com South Africa
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):